Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms.

Abdel-Wahab O, Pardanani A, Patel J, Wadleigh M, Lasho T, Heguy A, Beran M, Gilliland DG, Levine RL, Tefferi A.

Leukemia. 2011 Jul;25(7):1200-2. doi: 10.1038/leu.2011.58. Epub 2011 Apr 1. No abstract available.

2.

Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance.

Grossmann V, Kohlmann A, Eder C, Haferlach C, Kern W, Cross NC, Haferlach T, Schnittger S.

Leukemia. 2011 May;25(5):877-9. doi: 10.1038/leu.2011.10. Epub 2011 Feb 22. No abstract available.

PMID:
21339759
3.

EZH2 mutational status predicts poor survival in myelofibrosis.

Guglielmelli P, Biamonte F, Score J, Hidalgo-Curtis C, Cervantes F, Maffioli M, Fanelli T, Ernst T, Winkelman N, Jones AV, Zoi K, Reiter A, Duncombe A, Villani L, Bosi A, Barosi G, Cross NC, Vannucchi AM.

Blood. 2011 Nov 10;118(19):5227-34. doi: 10.1182/blood-2011-06-363424. Epub 2011 Sep 14.

4.

DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms.

Abdel-Wahab O, Pardanani A, Rampal R, Lasho TL, Levine RL, Tefferi A.

Leukemia. 2011 Jul;25(7):1219-20. doi: 10.1038/leu.2011.82. Epub 2011 Apr 26. No abstract available.

5.

LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations.

Pardanani A, Lasho T, Finke C, Oh ST, Gotlib J, Tefferi A.

Leukemia. 2010 Oct;24(10):1713-8. doi: 10.1038/leu.2010.163. Epub 2010 Aug 19.

PMID:
20724988
6.
7.

Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies.

Makishima H, Jankowska AM, Tiu RV, Szpurka H, Sugimoto Y, Hu Z, Saunthararajah Y, Guinta K, Keddache MA, Putnam P, Sekeres MA, Moliterno AR, List AF, McDevitt MA, Maciejewski JP.

Leukemia. 2010 Oct;24(10):1799-804. doi: 10.1038/leu.2010.167. Epub 2010 Aug 19. No abstract available.

PMID:
20724984
8.

Genetic defects in PRC2 components other than EZH2 are not common in myeloid malignancies.

Kroeze LI, Nikoloski G, da Silva-Coelho P, van Hoogen P, Stevens-Linders E, Kuiper RP, Schnittger S, Haferlach T, Pahl HL, van der Reijden BA, Jansen JH.

Blood. 2012 Feb 2;119(5):1318-9. doi: 10.1182/blood-2011-07-365213. No abstract available.

9.

New mutations and pathogenesis of myeloproliferative neoplasms.

Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA.

Blood. 2011 Aug 18;118(7):1723-35. doi: 10.1182/blood-2011-02-292102. Epub 2011 Jun 7. Review.

10.

Genetics of the myeloproliferative neoplasms.

Abdel-Wahab O.

Curr Opin Hematol. 2011 Mar;18(2):117-23. doi: 10.1097/MOH.0b013e328343998e. Review.

PMID:
21307773
11.

Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A.

Jankowska AM, Makishima H, Tiu RV, Szpurka H, Huang Y, Traina F, Visconte V, Sugimoto Y, Prince C, O'Keefe C, Hsi ED, List A, Sekeres MA, Rao A, McDevitt MA, Maciejewski JP.

Blood. 2011 Oct 6;118(14):3932-41. doi: 10.1182/blood-2010-10-311019. Epub 2011 Aug 9.

12.

DNMT3A mutations in myeloproliferative neoplasms.

Stegelmann F, Bullinger L, Schlenk RF, Paschka P, Griesshammer M, Blersch C, Kuhn S, Schauer S, Döhner H, Döhner K.

Leukemia. 2011 Jul;25(7):1217-9. doi: 10.1038/leu.2011.77. Epub 2011 May 3. No abstract available.

PMID:
21537334
13.

Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies.

Puda A, Milosevic JD, Berg T, Klampfl T, Harutyunyan AS, Gisslinger B, Rumi E, Pietra D, Malcovati L, Elena C, Doubek M, Steurer M, Tosic N, Pavlovic S, Guglielmelli P, Pieri L, Vannucchi AM, Gisslinger H, Cazzola M, Kralovics R.

Am J Hematol. 2012 Mar;87(3):245-50. doi: 10.1002/ajh.22257. Epub 2011 Dec 21.

14.

TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasms.

Martínez-Avilés L, Besses C, Álvarez-Larrán A, Torres E, Serrano S, Bellosillo B.

Ann Hematol. 2012 Apr;91(4):533-41. doi: 10.1007/s00277-011-1330-0. Epub 2011 Sep 9.

PMID:
21904853
15.

Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms.

Jankowska AM, Szpurka H, Tiu RV, Makishima H, Afable M, Huh J, O'Keefe CL, Ganetzky R, McDevitt MA, Maciejewski JP.

Blood. 2009 Jun 18;113(25):6403-10. doi: 10.1182/blood-2009-02-205690. Epub 2009 Apr 16.

16.

CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia.

Makishima H, Jankowska AM, McDevitt MA, O'Keefe C, Dujardin S, Cazzolli H, Przychodzen B, Prince C, Nicoll J, Siddaiah H, Shaik M, Szpurka H, Hsi E, Advani A, Paquette R, Maciejewski JP.

Blood. 2011 May 26;117(21):e198-206. doi: 10.1182/blood-2010-06-292433. Epub 2011 Feb 23.

17.

Activation of Ha-ras in human chronic granulocytic and chronic myelomonocytic leukaemia.

Gow J, Hughes D, Farr C, Hamblin T, Oscier D, Brown R, Padua RA.

Leuk Res. 1988;12(10):805-10.

PMID:
3059070
18.

Clinical Evaluation of a Novel Nine-Gene Panel for Ion Torrent PGM Sequencing of Myeloid Malignancies.

Ivanova M, Shivarov V, Pavlov I, Lilakos K, Naumova E.

Mol Diagn Ther. 2016 Feb;20(1):27-32.

PMID:
26476543
19.

TET2 mutations are associated with specific 5-methylcytosine and 5-hydroxymethylcytosine profiles in patients with chronic myelomonocytic leukemia.

Pérez C, Martínez-Calle N, Martín-Subero JI, Segura V, Delabesse E, Fernandez-Mercado M, Garate L, Alvarez S, Rifon J, Varea S, Boultwood J, Wainscoat JS, Cruz Cigudosa J, Calasanz MJ, Cross NC, Prósper F, Agirre X.

PLoS One. 2012;7(2):e31605. doi: 10.1371/journal.pone.0031605. Epub 2012 Feb 6.

20.

Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.

Tibes R, Bogenberger JM, Benson KL, Mesa RA.

Mol Diagn Ther. 2012 Oct;16(5):269-83. doi: 10.1007/s40291-012-0006-3. Review.

PMID:
23023734

Supplemental Content

Support Center